THERAPEUTIC AND DIAGNOSTIC GUIDELINES

1608 Guidelines to diagnose and treat peri-levator high-5 anal fistulas: Supralevator, suprasphincteric, extrasphincteric, high outersphincteric, and high intrarectal fistulas

Garg P, Yagnik VD, Dawka S, Kaur B, Menon GR

REVIEW

1625 Noninvasive imaging of hepatic dysfunction: A state-of-the-art review

Duan T, Jiang HY, Ling WW, Song B

1641 Small nucleolar RNA host gene 3 functions as a novel biomarker in liver cancer and other tumour progression

Shan DD, Zheng QX, Wang J, Chen Z

ORIGINAL ARTICLE

Basic Study

1656 LncRNA cancer susceptibility 20 regulates the metastasis of human gastric cancer cells via the miR-143-5p/MEMO1 molecular axis

Shan KS, Li WW, Ren W, Kong S, Peng LP, Zhuo HQ, Tian SB

Retrospective Cohort Study

1671 Aspartate transferase-to-platelet ratio index-plus: A new simplified model for predicting the risk of mortality among patients with COVID-19

Madian A, Eliwa A, Abdalla H, A Azeem Aly H

Retrospective Study

1681 Association of maternal obesity and gestational diabetes mellitus with overweight/obesity and fatty liver risk in offspring

Zeng J, Shen F, Zou ZY, Yang RX, Jin Q, Yang J, Chen GY, Fan JG

1692 Evaluating the accuracy of American Society for Gastrointestinal Endoscopy guidelines in patients with acute gallstone pancreatitis with cholecroolithiasis


SYSTEMATIC REVIEWS

1705 Risk of venous thromboembolism in children and adolescents with inflammatory bowel disease: A systematic review and meta-analysis

Zhang XY, Dong HC, Wang WF, Zhang Y
LETTER TO THE EDITOR

1718  Viral hepatitis: A global burden needs future directions for the management
       *Verma HK, Prasad K, Kumar P, Lvks B*

1722  Comment on “Artificial intelligence in gastroenterology: A state-of-the-art review”
       *Bjørsum-Meyer T, Koulaouzidis A, Bastrup G*
ABOUT COVER
Editorial Board Member of World Journal of Gastroenterology, Mauro Bortolotti, MD, Gastroenterologist, Internist, Former Director of 1st level and contract Professor at the Department of Internal Medicine and Gastroenterology of the S.Orsola-Malpighi Polyclinic, University of Bologna, via Massarenti 9, Bologna 40138, Italy. bormau@tin.it

AIMS AND SCOPE
The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING
The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2021 edition of Journal Citation Report® cites the 2020 impact factor (IF) for WJG as 5.742; Journal Citation Indicator: 0.79; IF without journal self cites: 5.590; 5-year IF: 5.044; Ranking: 28 among 92 journals in gastroenterology and hepatology; and Quartile category: Q2. The WJG’s CiteScore for 2020 is 6.9 and Scopus CiteScore rank 2020: Gastroenterology is 19/136.

RESPONSIBLE EDITORS FOR THIS ISSUE
Production Editor: Hua-Ge Yu; Production Department Director: Xu Gu; Editorial Office Director: Ze-Mao Gong.

<table>
<thead>
<tr>
<th>NAME OF JOURNAL</th>
<th>World Journal of Gastroenterology</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISSN</td>
<td>ISSN 1007-9327 (print) ISSN 2219-2840 (online)</td>
</tr>
<tr>
<td>LAUNCH DATE</td>
<td>October 1, 1995</td>
</tr>
<tr>
<td>FREQUENCY</td>
<td>Weekly</td>
</tr>
<tr>
<td>EDITORS-IN-CHIEF</td>
<td>Andrzej S Tarnawski</td>
</tr>
<tr>
<td>PUBLICATION DATE</td>
<td>April 28, 2022</td>
</tr>
<tr>
<td>COPYRIGHT</td>
<td>© 2022 Baishideng Publishing Group Inc</td>
</tr>
</tbody>
</table>

INSTRUCTIONS TO AUTHORS
[https://www.wjgnet.com/bpg/gerinfo/204](https://www.wjgnet.com/bpg/gerinfo/204)

GUIDELINES FOR ETHICS DOCUMENTS

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH
[https://www.wjgnet.com/bpg/gerinfo/240](https://www.wjgnet.com/bpg/gerinfo/240)

PUBLICATION ETHICS

PUBLICATION MISCONDUCT
[https://www.wjgnet.com/bpg/gerinfo/208](https://www.wjgnet.com/bpg/gerinfo/208)

ARTICLE PROCESSING CHARGE

STEPS FOR SUBMITTING MANUSCRIPTS
[https://www.wjgnet.com/bpg/gerinfo/239](https://www.wjgnet.com/bpg/gerinfo/239)

ONLINE SUBMISSION
[https://www.f6publishing.com](https://www.f6publishing.com)

© 2022 Baishideng Publishing Group Inc. All rights reserved. 7041 Kolb Center Parkway, Suite 160, Pleasanton, CA 94566, USA
E-mail: bpgoffice@wjgnet.com [https://www.wjgnet.com](https://www.wjgnet.com)
Aspartate transferase-to-platelet ratio index-plus: A new simplified model for predicting the risk of mortality among patients with COVID-19

Ali Madian, Ahmed Eliwa, Hytham Abdalla, Haitham A Azeem Aly

BACKGROUND
Coronavirus disease 2019 (COVID-19) has a spectrum of clinical syndromes with serious involvement of the lung and frequent effection of the liver and hemostatic system. Blood biomarkers are affordable, rapid, objective, and useful in the evaluation and prognostication of COVID-19 patients.

AIM
To investigate the association between aspartate transferase-to-platelet ratio index (APRI) and in-hospital mortality to develop a COVID-19 mortality prediction model.

METHODS
A multicenter cohort study with a retrospective design was conducted. Medical records of all consecutive adult patients admitted to Al-Azhar University Hospital (Assiut, Egypt) and Chest Hospital (Assiut, Egypt) with confirmed COVID-19 from July 1, 2020 to October 1, 2020, were retrieved and analyzed. The patient cohort was classified into the following two categories based on the APRI: (1) COVID-19 presenting with APRI ≤ 0.5; and (2) COVID-19 presenting with APRI (> 0.5 and ≤ 1.5). The association between APRI and all-cause in-hospital mortality was analyzed, and the new model was developed through logistic regression analyses.
RESULTS
Of the 353 patients who satisfied the inclusion criteria, 10% were admitted to the intensive care unit \((n = 36)\) and 7% died during the hospital stay \((n = 25)\). The median age was 40 years and 50.7% were male. On admission, 49% had aspartate transferase-dominant liver injury. On admission, APRI \((> 0.5 \text{ and } \leq 1.5)\) was independently associated with all-cause in-hospital mortality in unadjusted regression analysis and after adjustment for age and sex; after stepwise adjustment for several clinically relevant confounders, APRI was still significantly associated with all-cause in-hospital mortality. On admission, APRI \((> 0.5 \text{ and } \leq 1.5)\) increased the odds of mortality by five-times \((P < 0.006)\). From these results, we developed a new predictive model, the APRI-plus, which includes the four predictors of age, aspartate transferase, platelets, and serum ferritin. Performance for mortality was very good, with an area under the receiver operating curve of 0.90.

CONCLUSION
APRI-plus is an accurate and simplified prediction model for mortality among patients with COVID-19 and is associated with in-hospital mortality, independent of other relevant predictors.

Key Words: COVID-19; Aspartate transferase-to-platelet ratio index; Aspartate transferase; All-cause in-hospital mortality; Serum ferritin; SARS-CoV-2

©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.

Core Tip: Aspartate transferase-to-platelet ratio index-plus can be used to predict the severity of coronavirus disease 2019. The performance of the model for mortality was very good, with an area under the receiver operating curve of 0.90. This new prediction model could help in estimating the risk of mortality and may, therefore, assist in triaging patients. Moreover, our study confirmed that an aspartate transferase-dominant pattern, diabetes mellitus, leukocytosis, and increased ferritin levels are associated with fatal outcomes.

INTRODUCTION
The coronavirus disease 2019 (COVID-19) pandemic has prompted a global race to develop a variety of vaccine platforms. As a result, the first vaccine had been approved for emergency use by approximately 1 year from the beginning of the outbreak\([1]\). However, the ongoing limited availability of vaccines, particularly in low-income countries, means that the approach will not be sufficient to achieve global herd immunity. Therefore, effective and efficient allocation of health care resources is essential during the management of COVID-19 patients.

Blood biomarkers are affordable, rapid, readily available, and objective. It has been proven that blood biomarkers are useful in the evaluation and prognostication of COVID-19 patients. Many studies have demonstrated lymphopenia and thrombocytopenia among COVID-19 patients on hospital admission\([2, 3]\). Furthermore, both lymphopenia\([3, 4]\) and thrombocytopenia\([5]\) have been shown as predictive of COVID-19 severity and mortality.

Previously, many reports have cited hepatocellular injury with an aspartate aminotransferase (AST)-dominant pattern at hospital admission\([6, 7]\). In addition, it has been demonstrated that AST elevation at admission is associated with severe COVID-19 disease status and poor outcomes, including intensive care admission, need for mechanical ventilation\([7]\), and all-cause in-hospital mortality\([6]\). It has also been reported that elevated serum ferritin on admission is associated with fatal outcomes in patients with COVID-19\([8, 9]\).

Patients with COVID-19 associated with thrombocytopenia and hepatocellular injury progress to severe disease and poor outcomes. Previously, a simple scoring system, the AST-to-platelet ratio index (APRI), was developed to predict fibrosis in patients with chronic hepatitis C, being based upon routine blood biomarkers, including AST and platelets\([10]\). Using this as a premise, we hypothesized that it is possible to build a similar prediction model for patients with COVID-19 using objective, inexpensive, and readily available items.
The aim of the current study was to investigate whether APRI is associated with all-cause in-hospital mortality among patients with COVID-19 and develop a predictive model using objective and readily available factors.

MATERIALS AND METHODS

We conducted a multicenter retrospective cohort study using medical records of all consecutive adult patients admitted to Al-Azhar University Hospital in Assiut, Egypt and Chest Hospital in Assiut, Egypt with confirmed COVID-19 from July 1, 2020 to October 1, 2020, as the Egyptian Ministry of Health had allocated both hospitals for the management of COVID-19 patients. The inclusion criteria for patients were complete medical record data, hospitalized adults of ages ≥ 18 years, and COVID-19 diagnosis established by examination of nasopharyngeal swab specimens using reverse-transcriptase PCR [CerTest Viasure® SARS-CoV-2 Real Time PCR Detection Kit (CerTest; Biotec, Spain)] for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). All laboratory tests were operated in the accredited laboratories at the Clinical Pathology Departments (Microbiology and Immunology units) in Al-Azhar University Hospital and Chest Hospital. The exclusion criteria were pediatric patients of ages < 18 years, patients with known chronic liver disease or newly diagnosed with chronic liver disease at hospital admission, pregnant females, patients with incomplete data, patients with splenomegaly, splenectomy, chemotherapy, or radiotherapy within 1 mo of hospital admission, and patients on immunosuppressive therapy. In addition, we excluded any patient with marked fibrosis, as determined by both APRI and fibrosis-4 (FIB-4) scores (FIB-4 > 2.67 and APRI > 1.5). The institutional review boards approved the study protocol.

Cohort assignment

AST and platelets were measured within 24 h of hospital admission. The normal upper limit for AST was 40 U/L, and the normal upper limit and lower limit for platelets were 350 ’ 10^9/L and 150 ´ 10^9/L, respectively. APRI was calculated according to the following equation: “AST Level/ULN ÷ Platelet count × 100”[10]. We categorized our patient cohort into the following two categories based on APRI: (1) COVID-19 presenting with APRI ≤ 0.5; and (2) COVID-19 presenting with APRI (> 0.5 and ≤ 1.5).

Covariates

For every participant of our cohort, demographic criteria, including age, sex, and smoking status, comorbidities, including as diabetes mellites (DM), hypertension (HTN), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), and Deyo-Charlson index, and laboratory biomarkers, including complete blood count, liver enzymes, serum albumin, serum total bilirubin, blood urea, and serum creatinine and creatine kinase, were retrieved and analyzed. The FIB-4 was calculated by the following equation:

\[ \text{Age (year) × AST(U/L) ÷ Platelets (1000/μL) × √ALT(U/L)} \][11].

Outcome measurement

The primary outcome of interest was all-cause in-hospital mortality. The vital status of each patient in the study cohort was confirmed from hospital records. Follow-up of outcome was ended on October 15, 2020.

Statistical analysis

We summarized continuous variables as medians and interquartile ranges, and categorical variables were summarized as absolute numbers and percentages. We utilized unadjusted binary logistic regression for analyses of group differences. We performed a stepwise analysis adjusted for age and sex, as well as for relevant confounding factors, to investigate clinical confounders. Spearman’s correlation coefficients were utilized to analyze the relationships between variables. All P values calculated were two-tailed; values less than 0.05 were considered as indicative of statistical significance. Prediction performance was evaluated by the area under the curve of the receiver operating curve (AUROC). Overall fit of the models was evaluated by the Hosmer-Lemeshow test and the Bayesian information criterion. We used Stata Software (Stata Statistical Software: Release 16. College Station, TX, United States: Stata Corp LP) for data visualization and analysis.

RESULTS

Out of the 396 patients considered, 353 satisfied the inclusion criteria. Among those, 10% of the study cohort was admitted to the intensive care unit (n = 36) and 7% of the study participants succumbed during hospitalization (n = 25) (Figure 1). The median age at hospital admission was 40 years [interquartile range (IQR): 28-55 years], and 50.7% were males (n = 179) (Table 1). The frequency of
Table 1 Baseline demographic, clinical and laboratory characteristics of survivors and non-survivors’ groups

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Survivors, n = 328</th>
<th>Non-survivors, n = 25</th>
<th>Unadjusted OR</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age in yr, median (IQR)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 40</td>
<td>178 (98.89)</td>
<td>2 (1.11)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-60</td>
<td>112 (94.92)</td>
<td>6 (5.08)</td>
<td>4.76 (0.94-24.03)</td>
<td>0.05</td>
</tr>
<tr>
<td>&gt; 60</td>
<td>38 (69.09)</td>
<td>17 (30.91)</td>
<td>39.81 (8.82-179.59)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Male sex, n (%)</td>
<td>167 (93.30)</td>
<td>12 (6.70)</td>
<td>0.88 (0.39-2.00)</td>
<td>0.77</td>
</tr>
<tr>
<td>Comorbidities</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Chronic kidney disease, n (%)</td>
<td>4 (44.44)</td>
<td>5 (55.56)</td>
<td>20.25 (5.04-81.31)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Diabetes mellitus, n (%)</td>
<td>55 (77.46)</td>
<td>16 (22.54)</td>
<td>8.82 (3.70-20.98)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Chronic obstructive pulmonary disease, n (%)</td>
<td>55 (88.71)</td>
<td>7 (11.29)</td>
<td>1.93 (0.76-4.84)</td>
<td>0.16</td>
</tr>
<tr>
<td>Hypertension, n (%)</td>
<td>84 (84.00)</td>
<td>16 (16.00)</td>
<td>5.16 (2.19-12.12)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Deyo-Charlson index, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0-1</td>
<td>267 (97.45)</td>
<td>7 (2.55)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-3</td>
<td>60 (80.00)</td>
<td>15 (20.00)</td>
<td>9.53 (3.72-24.40)</td>
<td>0.0001</td>
</tr>
<tr>
<td>&gt; 3</td>
<td>1 (25.00)</td>
<td>3 (75.00)</td>
<td>114.42 (10.54-1241.77)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Laboratory biomarkers</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hemoglobin &lt; 12 mg/dL, n (%)</td>
<td>125 (92.59)</td>
<td>10 (7.41)</td>
<td>1.08 (0.47-2.48)</td>
<td>0.85</td>
</tr>
<tr>
<td>Total leukocytic count &gt; 11 × 10^9/L, n (%)</td>
<td>50 (80.65)</td>
<td>12 (19.35)</td>
<td>5.13 (2.21-11.89)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Platelet</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>150-350</td>
<td>248 (93.58)</td>
<td>17 (6.42)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 150 × 10^9/L, n (%)</td>
<td>32 (94.12)</td>
<td>2 (5.88)</td>
<td>0.91 (0.20-4.13)</td>
<td>0.90</td>
</tr>
<tr>
<td>&gt; 350 × 10^9/L, n (%)</td>
<td>48 (88.89)</td>
<td>6 (11.11)</td>
<td>1.82 (0.68-4.86)</td>
<td>0.23</td>
</tr>
<tr>
<td>Serum AST, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 40 U/L</td>
<td>229 (97.15)</td>
<td>7 (2.85)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-80 U/L</td>
<td>81 (84.38)</td>
<td>15 (15.63)</td>
<td>6.32 (2.49-16.05)</td>
<td>0.0001</td>
</tr>
<tr>
<td>&gt; 80 U/L</td>
<td>8 (72.73)</td>
<td>3 (27.27)</td>
<td>12.80 (2.78-58.83)</td>
<td>0.001</td>
</tr>
<tr>
<td>Serum ALT, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 40 U/L</td>
<td>217 (93.94)</td>
<td>14 (6.06)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40-80 U/L</td>
<td>90 (96.00)</td>
<td>10 (10.00)</td>
<td>1.72 (0.73-4.02)</td>
<td>0.20</td>
</tr>
<tr>
<td>&gt; 80 U/L</td>
<td>21 (95.45)</td>
<td>1 (4.55)</td>
<td>0.73 (0.09-5.89)</td>
<td>0.77</td>
</tr>
<tr>
<td>Serum albumin &lt; 3.5 g/dL, n (%)</td>
<td>112 (86.15)</td>
<td>18 (13.85)</td>
<td>4.95 (2.01-12.22)</td>
<td>0.001</td>
</tr>
<tr>
<td>Serum total bilirubin &gt; 1.5 mg/dL, n (%)</td>
<td>2 (40.00)</td>
<td>3 (60.00)</td>
<td>22.22 (3.52-140.03)</td>
<td>0.001</td>
</tr>
<tr>
<td>Serum creatinine &gt; 1.1 mg/dL for males; &gt; 0.95 mg/dL for females, n (%)</td>
<td>64 (80.00)</td>
<td>16 (20.00)</td>
<td>7.33 (3.09-17.34)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Serum ferritin &gt; 400 μg/L for males; &gt; 150 μg/L for females, n (%)</td>
<td>169 (87.56)</td>
<td>24 (12.44)</td>
<td>22.57 (3.01-168.86)</td>
<td>0.002</td>
</tr>
<tr>
<td>D-dimer &gt; 0.5 μg/mL</td>
<td>319 (92.73)</td>
<td>25 (7.27)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C-reactive protein ≥ 1 mg/L, n (%)</td>
<td>330 (92.70)</td>
<td>26 (7.30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Creatine kinase &gt; 117 IU/L, n (%)</td>
<td>0.00 (100.00)</td>
<td>0.00 (0.00)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>APRI, n (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>≤ 0.5</td>
<td>254 (95.85)</td>
<td>11 (4.15)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt; 0.5</td>
<td>74 (84.09)</td>
<td>14 (15.19)</td>
<td>4.36 (1.90-10.02)</td>
<td>0.001</td>
</tr>
</tbody>
</table>
Odds ratios were calculated by univariate logistic regression. Univariate logistic regression was used to calculate \( P \) value for the characteristics’ differences between survivors and survivors. ALT: Alanine transferase; APRI: AST-to-platelet ratio index; AST: Aspartate transferase; CRP: C-reactive protein; FIB-4: Fibrosis-4 score; IQR: Interquartile range; OR: Odds ratio.

Variables associated with in-hospital mortality were first assessed by univariate analysis. Significant variables from univariate analysis (\( P < 0.05 \)) or clinically relevant variables were then utilized for multivariate analysis by forward logistic regression to identify independent predictors associated with in-hospital death among patients with COVID-19.

Regression analysis: (1) Binary logistic regression analysis. Age, Deyo-Charlson index, CKD, DM, and HTN were the clinical predictors significantly associated with hospital mortality. Additionally, the unadjusted regression demonstrated that APRI, serum ferritin, total leukocytic count, serum total bilirubin, serum creatinine, serum AST, and serum albumin levels were significant biochemical markers associated with hospital death. There was no association between hospital mortality and sex, COPD, hemoglobin, platelets, serum alanine transferase (ALT), C-reactive protein (CRP), creatine kinase, or D-dimer levels (Table 1). (2) Multivariable logistic regression analysis. The APRI (\( > 0.5 - \leq 1.5 \)) at admission was significantly associated with hospital mortality in the unadjusted binary logistic regression analysis and remained a significant predictor of the odds of hospital mortality in model 1 adjusted for age and sex (Table 2). In addition, in model 2, after adjustment for several covariates, APRI was still a significant predictor of hospital mortality and associated with increased odds of hospital mortality by five times (\( P < 0.005 \)) (Table 2).

Variables in the best model (full model) for the prediction of death among patients with COVID-19 included APRI, age, CKD, DM, total leukocytic count, and serum ferritin. The AUROC for the prediction of death among patients with COVID-19 was 0.94 [95% confidence interval (CI): 0.90-0.98]. When the prediction model comprised APRI alone (APRI model), the AUROC for the prediction of mortality was 0.66 (95%CI: 0.56-0.76). The model with APRI, age, and serum ferritin (APRI-plus model) had better accuracy than the APRI model, and the AUROC became 0.90 (95%CI: 0.86-0.95) (\( P < 0.0001 \)) (Figure 2). In addition, the APRI-plus model showed good calibration (Hosmer-Lemeshow \( \chi^2 = 1.7, P = 0.97 \)) and was a better-fitting model than the full model (Bayesian information criterion 148.4) (Table 3).
Madian A et al. APRI-plus predicts mortality among COVID-19 patients

Table 2 Odds ratios of aspartate transferase-to-platelet ratio index associated mortality and 95% confidence intervals

<table>
<thead>
<tr>
<th>APRI</th>
<th>Unadjusted</th>
<th>Model I (Adjusted for age and sex)</th>
<th>Model II</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>OR</td>
<td>CI</td>
<td>P value</td>
</tr>
<tr>
<td>≤ 0.5</td>
<td>Ref.</td>
<td>1.00-1.00</td>
<td>Ref.</td>
</tr>
<tr>
<td>&gt; 0.5 - ≤ 1.5</td>
<td>4.36</td>
<td>1.90-10.02</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Covariates

- Age in yr
  - < 40: Ref.
  - 40-60: 1.75 (0.25-11.89) 0.56
  - > 60: 10.45 (1.51-72.09) 0.01
- Sex: 1.19 (0.39-3.65) 0.75
- CKD: 8.24 (1.37-49.53) 0.02
- DM: 7.77 (1.82-33.04) 0.006
- HTN: 0.25 (0.05-1.11) 0.07
- WBC: 4.20 (1.32-13.32) 0.01
- Albumin: 1.17 (0.33-4.09) 0.81
- Bilirubin: 10.10 (0.97-104.45) 0.05
- Ferritin: 12.94 (1.38-121.08) 0.02

Adjusted odds ratios for hospital mortality. Model 1 adjusted for age and sex; Model 2 adjusted for age, sex, diabetes mellitus, chronic kidney disease, hypertension, white blood cells, serum albumin, serum total bilirubin, and serum ferritin. APRI: Aspartate transferase-to-platelet ratio index; CKD: Chronic kidney disease; CI: Confidence interval; DM: Diabetes mellitus; HTN: Hypertension; IQR: Interquartile range; WBCs: White blood cells.

Table 3 Comparison of full model and aspartate transferase-to-platelet ratio index-plus in prediction of mortality among patients with coronavirus disease 2019 in the study cohort

<table>
<thead>
<tr>
<th></th>
<th>AUROC</th>
<th>HL-χ²</th>
<th>BIC</th>
</tr>
</thead>
<tbody>
<tr>
<td>APRI-plus model</td>
<td>0.90 (95% CI: 0.86-0.95)</td>
<td>0.97</td>
<td>148.4</td>
</tr>
<tr>
<td>Full model</td>
<td>0.94 (95% CI: 0.90-0.98)</td>
<td>0.95</td>
<td>164.9</td>
</tr>
</tbody>
</table>

AUROC: Area under the receiver operating characteristic curve; BIC: Bayesian information criterion; CI: Confidence interval; HL-χ²: Hosmer-Lemeshow χ² goodness-of-fit test.

The adjusted equation for the APRI-plus in patients with COVID-19 was \( P \) (in-hospital mortality) = - 0.18 + 0.06 \times (APRI > 0.5 and ≤ 1.5) (yes = 1, no = 0) + 0.004 \times age + 0.00013 \times ferritin.

Comparison with FIB-4

The AUROC for FIB-4 score was 0.72 (95% CI: 0.61-0.82). Upon comparison of the APRI-plus with FIB-4, the AUROC was significantly higher for APRI-plus, at 0.92 (95% CI: 0.86-0.98) \( P < 0.0001 \) (Figure 3).

Association of D-dimer with inflammatory markers

D-dimer was examined as a marker of thrombosis. On admission, platelets, serum ferritin, CRP, total leukocytic count, and AST were correlated with D-dimer \( (r = 0.1; P < 0.03, r = 0.4; P < 0.0001, r = 0.4; P < 0.0001, r = 0.1; P < 0.01, and r = 0.1; P < 0.03, respectively) \).

Association of APRI components with markers of inflammation

Serum ferritin, CRP, and total leukocytic count were investigated as inflammatory markers. Serum levels of AST were correlated with serum ferritin \( (r = 0.2; P < 0.0001) \), CRP \( (r = 0.2; P < 0.0001) \), and total leukocytic count \( (r = 0.1; P < 0.007) \). Platelets were correlated with serum ferritin \( (r = 0.1; P = 0.04) \), CRP \( (r = 0.07; P = 0.1) \), and total leukocytic count \( (r = 0.1; P = 0.05) \).
DISCUSSION

In the current study, we developed APRI-plus, a new, simple, inexpensive, and objective clinical score that is significantly associated with mortality among patients with COVID-19. APRI (> 0.5 and ≤ 1.5) increased the odds of mortality by five-fold. Since patients with chronic liver disease were excluded from participation in our analysis, this association is likely due to inflammation related to COVID-19 and the direct impact of SARS-Cov-2 on the liver and hemostatic system.

We observed a significant difference in AST between survivors and nonsurvivors at hospital admission. The AST-dominant pattern of hepatocellular injury among patients with COVID-19 has been reported many times in previous studies[6,7]. Likewise, the levels of serum ferritin were significantly higher among nonsurvivors. Platelets have been reported to be one of the strongest indicators of adverse outcomes and mortality among patients with COVID-19[2,3]. However, in our cohort, we did not find any statistically significant difference in platelets between survivors and nonsurvivors. Thus, platelets alone are less ideal in predicting outcomes among patients with COVID-19.
APRI includes AST in the numerator and platelets in the denominator. These criteria make the APRI score a better predictor of COVID-19 outcomes than AST or platelets alone. Regarding its accuracy in predicting mortality among patients with COVID-19, the APRI has an AUROC of 0.66. However, when age and serum ferritin were incorporated in the regression model (APRI-plus model), the performance of the model had an AUROC of 0.90. In contrast, compared with another noninvasive score, FIB-4 (composed of AST, ALT, age, and platelets), we found that the AUROC was significantly lower for FIB-4 (0.72). In line with our findings, the reported AUROC in an earlier study for FIB-4 was 0.79[11]. Using APRI-plus, it is possible to predict mortality among patients with COVID-19 with good performance.

Liver stiffness among patients with COVID-19 is likely to be multifactorial. Hepatic congestion, hepatocellular injury, and systemic inflammation may all play a role in the development of liver stiffness among patients with COVID-19. It has been reported that COVID-19 is associated with increased pressure within the right ventricle[12]; thus, this may result in hepatic venous congestion and liver stiffness[11].

Severe liver injury caused by SARS-CoV-2 Likely results in mitochondrial damage and defective clearance of AST, leading to an AST-dominant pattern. At the onset of severe SARS-CoV-2 infection, severe liver injury is likely associated with extensive inflammation, hepatocyte swelling, and tissue edema, especially among patients with an AST-dominant pattern. Similar to acute viral hepatitis, extensive necroinflammatory activity among patients with COVID-19 increases liver stiffness[13].

Our cohort revealed that platelet count did not have a significant association with mortality. Interestingly, not all previous studies have found platelet counts to be a predictor of COVID-19 mortality[14]. Inflammatory mediators associated with SARS-CoV-2 infection may result in the activation of platelets. Activated platelets have two pathways. First, enhanced platelet clearance/sequestration from circulation by the spleen results in thrombocytopenia. Second, consumptive coagulopathy, such as inflammation-mediated endothelial damage/activation in addition to platelet activation, leads to the formation of platelet aggregates through systemic circulation and/or pulmonary circulation[15]. Therefore, we can speculate that the early phase of SARS-CoV-2 infection results in the activation of platelets followed by thrombocytopenia. Our results support this speculation, as inflammatory markers (CRP, serum ferritin, and leukocytosis) were correlated with D-dimer. This may suggest that the mechanism and progression of platelet activation rather than platelet number were associated with worse outcomes.

The rising question is why we did not find a significant difference in D-dimer between the survivor and nonsurvivor groups. This could be explained by COVID-19-associated coagulopathy. Coagulation changes associated with COVID-19 have the following three proposed stages: stage 1 presents with raised D-dimer; stage 2 presents with raised D-dimer together with modestly increased prothrombin time/international normalization ratio, activated partial thromboplastin time, and mild thrombocytopenia; and stage 3 presents with critical illness and laboratory markers, directing towards classic disseminated intravascular coagulopathy[14]. Therefore, our data may be retrieved early during platelet activation and before firing of stage 1 COVID-19-associated coagulopathy.

**Limitations of the current study**
The retrospective design of the study reflected the association between APIR-plus and risk of mortality among patients with COVID-19 but did not reflect causality. We used APIR at the time of admission for group categorization without knowing follow-up changes. Because of the lack of follow-up, we do not know whether these necroinflammatory changes were self-limiting or progressive. Moreover, we do not know the extent and duration of resolution. We did not evaluate platelet activity, fibrin degradation products, or coagulation profiles. Elastography should be evaluated in different age groups to dissect the impact of age from COVID-19 on liver stiffness. Validation of the APIR-plus is required.

**CONCLUSION**
The current study showed that, on admission, APIR-plus among patients with COVID-19 has good performance in predicting mortality. A prediction model could help stratify the risk of mortality. This association may be explained by the impact of SARS-CoV-2 infection on the liver and hemostatic system. Further studies are required to investigate this association.

**ARTICLE HIGHLIGHTS**

**Research background**
Coronavirus disease 2019 (COVID-19) has a spectrum of clinical syndromes with serious involvement of the lung and frequent effection of the liver and hemostatic system.
Research motivation
Development of a prediction model using objective, inexpensive, and readily available items is needed for patients with COVID-19.

Research objectives
To investigate whether the aspartate transferase-to-platelet ratio index (APRI) is associated with all-cause in-hospital mortality among patients with COVID-19 and develop a predictive model using objective and readily available factors.

Research methods
A retrospective cohort study was carried out with 353 consecutive adult patients admitted to Al-Azhar University Hospital (Assiut, Egypt) and Chest Hospital (Assiut, Egypt) with confirmed COVID-19 from July 1, 2020 to October 1, 2020.

Research results
The prediction model comprised APRI alone (APRI model), and the area under the receiver operating curve (AUROC) for the prediction of mortality was 0.66 [95% confidence interval (CI): 0.56-0.76]. A modified model of APRI that included age and serum ferritin (APRI-plus model) had better accuracy than the APRI model, as the AUROC became 0.90 (95% CI: 0.86-0.95) (P < 0.0001).

Research conclusions
APRI-plus among patients with COVID-19 showed good performance in predicting mortality. A prediction model could help stratify the risk of mortality.

Research perspectives
Further studies are required to investigate this association. Validation of the APRI-plus is required.

ACKNOWLEDGEMENTS
We appreciate the effort of all medical staff and technicians who agreed to participate in this study.

FOOTNOTES
Author contributions: Madian A was responsible for the study conception and design, the data acquisition, analysis and interpretation, the statistical analysis, and writing of the first draft of the manuscript; Eliwa A and Abdalla H contributed to the data collection; Azeem HA reviewed the manuscript and provided critical scientific input; all authors approved the final manuscript.

Institutional review board statement: The study was approved by the Ethics Committee of Faculty of Medicine, Al-Azhar University, Assiut, Egypt.

Informed consent statement: No informed consent was required, as patient identity is not revealed in the retrospective analysis.

Conflict-of-interest statement: No benefits in any form have been received or will be received from a commercial party related directly or indirectly to the subject of this article.

Data sharing statement: The original anonymous dataset is available on request from the corresponding author at a.madian@azhar.edu.eg.

STROBE statement: The authors have read the STROBE Statement—checklist of items, and the manuscript was prepared and revised according to the STROBE Statement—checklist of items.

Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/

Country/Territory of origin: Egypt

ORCID number: Ali Madian 0000-0002-8322-7504; Ahmed Eliwa 0000-0003-0818-3086; Hytham Abdalla 0000-0001-5377-6572; Haitham A Azeem Aly 0000-0001-5732-5277.
REFERENCES


